Annual report pursuant to Section 13 and 15(d)

Licenses Acquired - Additional Information (Detail)

v3.20.1
Licenses Acquired - Additional Information (Detail)
1 Months Ended 12 Months Ended
Dec. 17, 2019
USD ($)
Milestone
agreement
$ / shares
shares
Aug. 23, 2019
USD ($)
Feb. 11, 2019
USD ($)
Aug. 02, 2018
USD ($)
Jul. 03, 2018
$ / shares
shares
Jan. 03, 2018
USD ($)
Nov. 30, 2017
USD ($)
Nov. 20, 2017
USD ($)
Jul. 03, 2017
USD ($)
May 31, 2017
USD ($)
Apr. 25, 2017
USD ($)
Mar. 17, 2017
USD ($)
Oct. 15, 2015
USD ($)
Sep. 30, 2015
USD ($)
shares
May 11, 2015
USD ($)
$ / shares
shares
Jun. 30, 2019
USD ($)
Nov. 30, 2017
USD ($)
Mar. 31, 2017
USD ($)
Jan. 31, 2017
USD ($)
Oct. 31, 2016
USD ($)
shares
May 31, 2016
USD ($)
Apr. 30, 2015
USD ($)
Apr. 28, 2015
USD ($)
Mar. 31, 2015
USD ($)
Feb. 28, 2015
USD ($)
Dec. 31, 2019
USD ($)
installment
Dec. 31, 2018
USD ($)
Dec. 31, 2015
USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Total consideration                                                   $ 2,400,000 $ 1,200,000  
Research and Development in Process                                                   6,090,000 4,050,000  
Payments for Fees             $ 100,000                   $ 2,100,000                      
Stock Issued During Period, Shares, Issued for Services | shares                           136,830                            
Stock Issued During Period, Value, Issued for Services                           $ 600,000                       500,000    
Research and Development Expense                                                   81,326,000 87,383,000  
Share Price | $ / shares         $ 3.04                                              
Payment of Upfront Fees                                                   1,000,000    
Revenue Recognition Milestone Method Payments Due                                                   14,500,000    
Proceeds from Issuance of Common Stock     $ 13,100,000                                                  
Stock Issued During Period, Shares, New Issues | shares         164,473                                              
Revenue from Contract with Customer, Including Assessed Tax                                                   34,921,000 23,376,000  
Cost, Maintenance                                                   50,000 25,000  
Dana Farber Cancer Institute [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Annual Maintenance Fee Payable                           50,000                            
Collaborative Agreements with TGTX [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Payments for Fees                               $ 1,000,000                   500,000    
NeuPharma [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Research and Development in Process                                               $ 1,000,000        
NeuPharma [Member] | Collaborative Agreements with TGTX [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Payments for Fees                                                   1,600,000 3,000,000  
NeuPharma [Member] | Development Milestone [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Revenue Recognition Milestone Method Payments Due                                               40,000,000        
NeuPharma [Member] | Sale Milestone [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Revenue Recognition Milestone Method Payments Due                                               40,000,000        
NeuPharma [Member] | Regulatory Approvals To Commercialize Products [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Revenue Recognition Milestone Method Payments Due                                               22,500,000        
City of Hope (COH) [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Payment of Upfront Fees                                             $ 2,000,000          
UCLA MB-105 [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Revenue Recognition Milestone Method Payments Due                       $ 14,300,000                                
Tamid [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Research and Development in Process                                                   0 $ 0  
Dana Farber Cancer Institute [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Shares Issued, Price Per Share | $ / shares                             $ 0.065                          
Stock Issued During Period, Shares, Issued for Services | shares                             500,000                          
Stock Issued During Period, Value, Issued for Services                             $ 32,500                          
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners                                                     5.00%  
Proceeds from Issuance of Common Stock                                                     $ 10,000,000  
Dana Farber Cancer Institute [Member] | First Commercial Sale Milestone [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Revenue Recognition Milestone Method Payments Due                           21,500,000                            
Dana Farber Cancer Institute [Member] | Additional Sales Milestone [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Revenue Recognition Milestone Method Payments Due                           $ 60,000,000                            
Mustang Bio, Inc [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Royalty Guarantees, Commitments, Amount                                               $ 1,000,000        
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners                                               10.00%        
Annual Maintenance Fee Payable                                               $ 1,000,000        
Mustang Bio, Inc [Member] | Agreement With City Of Hope [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Payment of Upfront Fees               $ 300,000                                        
Mustang Bio, Inc [Member] | Financial Milestone [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Revenue Recognition Milestone Method Payments Due                                               14,500,000        
Additional Minimum Annual Royalty Payable                                               2,000,000        
Cellvation Inc [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Payment of Upfront Fees                                                   0 1,000  
Teva Pharmaceutical Industries Ltd [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Payments for Fees                                                       $ 500,000
Jubilant Biosys Ltd [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Revenue Recognition Milestone Method Payments Due                                                   $ 87,200,000    
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners                                                   50.00%    
Payment Of Upfront Licensing Fee                                         $ 2,000,000              
Jubilant Biosys Ltd [Member] | Sale Milestone [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Milestone Method Revenue Additional Payments Eligible To Receive                                         89,000,000              
Jubilant Biosys Ltd [Member] | Regulatory Approvals To Commercialize Products [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Revenue Recognition Milestone Method Payments Due                                         59,500,000              
Jubilant Biosys Ltd [Member] | Completion Of Three Clinical Development Milestones For Two Licensed Products [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Revenue Recognition Milestone Method Payments Due                                                   $ 25,500,000    
Jubilant Biosys Ltd [Member] | Five Regulatory Approvals And First Commercial Sales [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Revenue Recognition Milestone Method Payments Due                                                   61,700,000    
Jubilant Biosys Ltd [Member] | Three Sales Milestones Based On Aggregate Net Sales [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Revenue Recognition Milestone Method Payments Due                                                   89,000,000    
Jubilant Biosys Ltd [Member] | Clinical Development And Regulatory Milestones [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Revenue Recognition Milestone Method Payments Due                                         $ 89,000,000              
Columbia University [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Payment of Upfront Fees                                                     300,000  
Columbia University [Member] | Maximum                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Revenue Recognition Milestone Method Payments Due                                     $ 5,500,000                  
Adimab, LLC Collaboration Agreement | Regulatory Approvals To Commercialize Products [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Revenue Recognition Milestone Method Payments Due                         $ 4,800,000                              
Adimab, LLC Collaboration Agreement | Clinical Development And Regulatory Milestones [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Revenue Recognition Milestone Method Payments Due                         $ 7,100,000                              
License Agreement with NICHD | Cyprium [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Research and Development Expense                                                   0 0  
Payment of Upfront Fees                                   $ 100,000                    
Revenue Recognition Milestone Method Payments Due                                   15,000,000                    
License Agreement with NICHD | Cyprium [Member] | First Commercial Sale Milestone [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Revenue Recognition Milestone Method Payments Due                                   1,000,000                    
License Agreement with NICHD | Cyprium [Member] | Clinical Development And Regulatory Milestones [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Revenue Recognition Milestone Method Payments Due                                   $ 1,700,000                    
License Agreement with NICHD | Cyprium [Member] | Minimum                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Sales royalties (as a percent)                                   15.00%                    
License Agreement with NICHD | Cyprium [Member] | Maximum                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Sales royalties (as a percent)                                   20.00%                    
Spacer License with City of Hope                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Research and Development in Process                                                   0 0  
IV Tramadol [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Payment Of Upfront Licensing Fee                                                   3,000,000    
Baergic[Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Number of license agreement | agreement 2                                                      
AZ License [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Payment of Upfront Fees $ 75,000,000                                                      
Cincinnati License [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Payment Of Upfront Licensing Fee $ 6,500,000                                                      
Pentameter [Member] | City of Hope (COH) [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Minimum Annual Royalty Payable                                           $ 750,000            
Pentameter [Member] | City of Hope (COH) [Member] | Development Milestone [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Revenue Recognition Milestone Method Payments Due                                           5,500,000            
Pentameter [Member] | City of Hope (COH) [Member] | Sale Milestone [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Revenue Recognition Milestone Method Payments Due                                           26,000,000            
Royalty [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Revenue from Contract with Customer, Including Assessed Tax                                                   100,000 400,000  
Checkpoint [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Research and Development in Process                                                   0 1,000,000  
Checkpoint [Member] | Collaborative Agreements with TGTX [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Revenue Recognition Milestone Method Payments Due                                                   9,400,000    
Checkpoint [Member] | First Commercial Sale Milestone [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Revenue Recognition Milestone Method Payments Due                                                   28,600,000    
Checkpoint [Member] | Additional Sales Milestone [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Revenue Recognition Milestone Method Payments Due                                                   60,000,000    
Checkpoint [Member] | Regulatory Filings And Commercial Sales In Specified Territories [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Revenue Recognition Milestone Method Payments Due                                                   19,200,000    
Mustang [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Research and Development in Process                                                   1,350,000 1,275,000  
Mustang [Member] | Financial Milestone [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Revenue Recognition Milestone Method Payments Due                     $ 200,000                                  
Mustang [Member] | Nationwide Children's Hospital License Agreement (MB-108)                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Payments for Fees                                                   200,000    
Revenue Recognition Milestone Method Payments Due                                                   152,800,000    
Mustang [Member] | CSL Behring Licence MB-107                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Research and Development Expense                                                   200,000    
Payment of Upfront Fees   $ 200,000                                                    
Revenue Recognition Milestone Method Payments Due   $ 1,200,000                                                    
Helocyte [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Research and Development in Process                                                   450,000 1,521,000  
Payments For Research And Development Expenses                                                   0 1,500,000  
Helocyte [Member] | License Agreement with NIAD                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Research and Development in Process                                                   500,000 0  
Payment of Upfront Fees                                                   500,000    
Minimum Annual Royalty Payable                                                   55,000    
Additional Minimum Annual Royalty Payable                                                   $ 1,050,000    
Payment Of Upfront Fees, Number Of Installments | installment                                                   3    
Helocyte [Member] | Triplex [Member] | Development Milestone [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Revenue Recognition Milestone Method Payments Due                                                     26,000,000  
Helocyte [Member] | Triplex [Member] | Sale Milestone [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Revenue Recognition Milestone Method Payments Due                                                     3,700,000  
Helocyte [Member] | Triplex [Member] | Financial Milestone [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Revenue Recognition Milestone Method Payments Due                                                     7,500,000  
Caelum [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Research and Development in Process                                                   $ 0 252,000  
Licensing Agreements [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Total consideration                                           $ 45,000            
Licensing Agreements [Member] | Dana Farber Cancer Institute [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Research and Development in Process                                                     1,000,000  
Licensing Agreements [Member] | Cellvation Inc [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Stock Issued During Period, Shares, Issued for Services | shares                                       500,000                
Payment of Upfront Fees                                       $ 300,000                
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners                                       5.00%                
Licensing Agreements [Member] | Cellvation Inc [Member] | Development Milestone [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Revenue Recognition Milestone Method Payments Due                                       $ 6,200,000                
Licensing Agreements [Member] | Cellvation Inc [Member] | Sale Milestone [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Revenue Recognition Milestone Method Payments Due                                       6,000,000                
Licensing Agreements [Member] | Cellvation Inc [Member] | Minimum                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Additional Minimum Annual Royalty Payable                                       50,000                
Licensing Agreements [Member] | Cellvation Inc [Member] | Maximum                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Additional Minimum Annual Royalty Payable                                       200,000                
Licensing Agreements [Member] | IV Tramadol [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Payments for Fees                                                 $ 3,000,000      
Licensing Agreements [Member] | AZ License [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Stock Issued During Period, Shares, Issued for Services | shares 2,492,192                                                      
Percentage of common shares issued (in percent) 19.95%                                                      
Payment of Upfront Fees $ 3,000,000                                                      
Revenue Recognition Milestone Method Payments Due $ 130,000,000                                                      
Number of net sales milestones | Milestone 3                                                      
Licensing Agreements [Member] | AZ License [Member] | Valuation Technique, Discounted Cash Flow [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Percentage of lack of marketability 44.60%                                                      
Percentage of weighted average cost of capital 20.50%                                                      
Net of debt in per share | $ / shares $ 0.029                                                      
Amount of net of debt utilized $ 100,000                                                      
Licensing Agreements [Member] | AZ License [Member] | Maximum                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Issuance of anti-dilution protection of shares $ 75,000,000                                                      
Licensing Agreements [Member] | Cincinnati License [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Stock Issued During Period, Shares, Issued for Services | shares 624,922                                                      
Percentage of common shares issued (in percent) 5.00%                                                      
Payment of Upfront Fees $ 200,000                                                      
Reimbursement of past patent expenses 30,000                                                      
Revenue Recognition Milestone Method Payments Due $ 21,000,000                                                      
Number of net sales milestones | Milestone 4                                                      
Licensing Agreements [Member] | Cincinnati License [Member] | Valuation Technique, Discounted Cash Flow [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Percentage of lack of marketability 44.60%                                                      
Percentage of weighted average cost of capital 20.50%                                                      
Net of debt in per share | $ / shares $ 0.029                                                      
Amount of net of debt utilized $ 100,000                                                      
Licensing Agreements [Member] | Cincinnati License [Member] | Maximum                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Issuance of anti-dilution protection of shares $ 15,000,000                                                      
Secondary License [Member] | Cellvation Inc [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Payment of Upfront Fees                                       50,000                
Revenue Recognition Milestone Method Payments Due                                       300,000                
Second TBI License [Member] | Cellvation Inc [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Minimum Annual Royalty Payable                                       $ 100,000                
AR CD123 License [Member] | City of Hope (COH) [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Research and Development in Process                                                   300,000 0  
Revenue Recognition Milestone Method Payments Due                                                   14,500,000    
AR IL-13 License [Member] | City of Hope (COH) [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Revenue Recognition Milestone Method Payments Due                                                   14,500,000    
HER2 Technology License [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Research and Development in Process                                                   0 200,000  
Payment of Upfront Fees                   $ 600,000                                    
Revenue Recognition Milestone Method Payments Due                   14,900,000                                    
Annual Maintenance Fee Payable                   50,000                                    
CS1 License [Member] | Mustang [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Research and Development in Process                                                   200,000 0  
Payment of Upfront Fees                 $ 600,000                                      
Revenue Recognition Milestone Method Payments Due                   14,900,000                                    
Annual Maintenance Fee Payable                   50,000                                    
PSCA [Member] | Mustang [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Research and Development in Process                                                   200,000 0  
Payment of Upfront Fees                 300,000                                      
Revenue Recognition Milestone Method Payments Due                   14,900,000                                    
Annual Maintenance Fee Payable                   $ 50,000                                    
University of California [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Research and Development in Process                                                   300,000 0  
Fred Hutchinson Cancer Research Center License [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Research and Development in Process                                                   0 0  
Payment of Upfront Fees                 300,000                                      
Revenue Recognition Milestone Method Payments Due                 39,100,000                                      
Annual Maintenance Fee Payable                 $ 50,000                                      
Harvard College License [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Research and Development in Process                                                   0 0  
Revenue Recognition, Sales and Marketing Milestone Method Payments Due                                                   16,700,000    
CITY OF HOPE IV ICV License [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Research and Development in Process                                                   0 0  
Payment of Upfront Fees                                   $ 100,000                    
Revenue Recognition Milestone Method Payments Due                                   $ 100,000                    
CITY OF HOPE IV ICV License [Member] | Mustang [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Research and Development in Process                                               $ 200,000        
City of Hope MB-101 (IL13R2 CAR T for Glioblastoma) [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Research and Development in Process                                                   0 0  
Manufacturing License [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Total consideration           $ 75,000                                            
Research and Development in Process                                                     100,000  
St Jude Childrens Research Hospital [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Research and Development in Process                                                   0 $ 1,000,000  
Revenue Recognition Milestone Method Payments Due       $ 13,500,000                                                
Additional Annual License fee       100,000                                                
Annual license fee       $ 1,000,000                                                
Anti - GTR License [Member] | Checkpoint [Member] | Collaborative Agreements with TGTX [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Revenue Recognition Milestone Method Payments Due                                                   21,500,000    
Anti - GTR License [Member] | Checkpoint [Member] | Clinical Development Milestone [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Revenue Recognition Milestone Method Payments Due                                                   7,000,000    
Anti - GTR License [Member] | Checkpoint [Member] | Commercial Sales In Specified Territories [Member]                                                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                        
Revenue Recognition Milestone Method Payments Due                                                   $ 14,500,000